Nacartocin
Source Nacartocin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Nacartocin is a synthetic analogue of oxytocin, modified to enhance its ability to promote sodium excretion (natriuresis). Pre‑clinical studies in rabbits, rats, and cats have examined its cardiovascular and renal effects, indicating a potent natriuretic action and modest influences on blood pressure. The peptide is investigated primarily as a research tool to understand oxytocin‑related renal physiology.
Mechanism of Action
Nacartocin appears to act by inhibiting tubular sodium reabsorption in the kidney, leading to increased urinary sodium loss. In animal models it also reduces total peripheral resistance, producing a fall in blood pressure under anesthesia, while in conscious rats it may cause a slight, prolonged blood‑pressure rise. These actions are consistent with activation of oxytocin‑type receptors that influence renal and vascular tone, although the exact receptor subtype has not been defined in the cited work.
What the Research Shows
Four animal studies characterize Nacartocin. In rabbits, intravenous administration produced measurable cardiovascular effects compared with oxytocin. In rats, the peptide was nearly three‑fold more potent than oxytocin as a natriuretic agent, decreasing total peripheral resistance and lowering blood pressure in anesthetized animals, while causing a modest, sustained blood‑pressure increase in conscious rats. In cats, intravenous doses of 0.05‑10 µg/kg markedly raised sodium excretion with only slight potassium changes. A comparative study with the ACTH fragment 1‑24 showed Nacartocin’s natriuretic effect to be substantially stronger than that of the peptide fragment. Across studies, the primary outcome was enhanced sodium loss without major adverse events reported.
Reported Benefits
Animal data suggest Nacartocin is a potent natriuretic peptide, outperforming native oxytocin by up to three times in promoting sodium excretion. This property could be valuable for probing renal sodium handling mechanisms. Additionally, its ability to lower total peripheral resistance offers a tool for studying vascular responses linked to oxytocin‑like peptides.
Limitations of the Evidence
Evidence is limited to acute experiments in rabbits, rats, and cats; no human or chronic studies are reported. Blood‑pressure effects differ between anesthetized and conscious states, indicating a complex hemodynamic profile. The exact receptor pathways remain undefined, and safety data are sparse, restricting translational conclusions.
Safety Considerations
The abstracts do not describe overt toxicity or adverse reactions at the tested doses, but they also lack systematic safety assessments. Observed blood‑pressure changes—decreases under anesthesia and slight increases in conscious rats—highlight the need for caution when extrapolating to other species. Without human data, safety cannot be assumed.
How It Is Administered
All reported experiments used intravenous injection of Nacartocin. Effective doses ranged from 0.05 to 10 µg per kilogram body weight (approximately 0.05‑10 nmol/kg) in cats, with similar dosing strategies implied in rat and rabbit studies. Formulation details beyond peptide solution are not provided.
Routes of Administration
No administration routes recorded yet.
Goals & Uses
No goal associations recorded yet.
Contraindications
No contraindications recorded yet.
Adverse Effects
No adverse effects recorded yet.
Drug Interactions
No drug interactions recorded yet.
Population Constraints
No population constraints recorded yet.
Regulatory Status
No regulatory status recorded yet.
Evidence & Sources
- Journal ArticleLowGersl V, Hajzlerová K, Troppová V1985-01-01T00:00:00.000000Z
- Journal ArticleLowMachová A, Schreiber V1986-01-01T00:00:00.000000Z
- Journal ArticleLowSkopková J, et al.1984-01-01T00:00:00.000000Z
- Journal ArticleLowHrbas P, et al.1984-01-01T00:00:00.000000Z
Frequently Asked Questions
What is the primary pharmacological effect of Nacartocin?
Nacartocin mainly enhances urinary sodium excretion by inhibiting tubular sodium reabsorption, producing a stronger natriuretic response than oxytocin in several animal models.
Has Nacartocin been tested in humans?
No human studies are cited. All reported data come from acute experiments in rabbits, rats, and cats, so its effects and safety in people remain unknown.
Does Nacartocin affect blood pressure?
Yes. In anesthetized rats it lowered blood pressure by reducing total peripheral resistance, whereas in conscious rats it caused a slight, prolonged increase. Effects may vary with physiological state.
How is Nacartocin administered in research settings?
Research studies have administered Nacartocin intravenously, using dose ranges of 0.05‑10 µg/kg. Specific formulation details are not described in the abstracts.
What are the safety considerations for using Nacartocin?
Safety data are limited; no adverse events were reported in the animal studies, but blood‑pressure changes suggest potential cardiovascular effects. Caution is advised when interpreting results beyond the experimental conditions.